

In re Application of:

Dario NERI et al.

Serial No.: 09/194,356

Group Art Unit: 1642

Filed: September 2, 1999

Examiner: Alana M. Harris

For: ANTIBODIES TO ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND

USES

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## **Timing and Fees**

	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
		within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
$\boxtimes$	Under	37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods			

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
a final rejection under 37 C.F.R. 1.113;

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

19/CS/2006 MAHHED1 00000090 09194356

02 FC:1806

185.09 02

is acco	ompanied by:
	the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
$\boxtimes$	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
a final	action under 37 C.F.R. § 1.113;
termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
OR a	notice of allowance under 37 C.F.R. § 1.311;
is filed	on or before payment of the issue fee; AND is accompanied by:
	tement as specified in 37 C.F.R. $\S$ 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. $\S$ 1.17(p).
nder 37	C.F.R. 1.97(e)
	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
<u>ıls</u>	
ancest	or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
-	s of materials listed but not attached were cited in an international search dated
Not re	equired by 37 CFR § 1.98.
Copie	s of the materials listed are attached (except for the foregoing).
	37 C.F. f the fold a final terminal terminal terminal terminal is filed the state \$180.0 mder 37

Non-Engli	sh Language References				
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:				
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> </ul>				
	Translation of other relevant information on foreign search report				
Other Info	rmation				
Payment of Fees Due (If Any):  A check for \$180.00 covering the fee identified above is attached.					
Ple	ase charge to Deposit Account No. 13-3402 \$ for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Jelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0003

Date: October 5, 2006

AJZ:hlw

K:\Ellis-3\Information Disclosure Statement 10.5.06.doc



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449A/PTO				Complete if Known		
					Application Number	09/194,356	
INFORMATION DISCLOSURE					Filing Date	September 2, 1999	
	STATEMENT BY APPLICANT				First Named Inventor	Dario NERI et al.	
					Group Art Unit	1642	
	(use as many sheets as necessary)				Examiner Name	Alana M. Harris	
_	Sheet	1	of	1	Attorney Docket Number	ELLIS-0003	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	1	MATSUURA et al., "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma," Proc.Natl.Acad.Sci., vol. 82, pp 6517-6521, October 1985.				
	2	MATSUURA et al., "An α-N-Acetylgalactosaminylation at the Threonine Residue of a Defined Peptide Sequence Creates the Oncofetal Peptide Epitope in Human Fibronectin," The Journal of Biological Chemistry, vol. 264, no. 18, pp 10472-10476, 1989.				
	3	MATSUURA et al., "The Oncofetal Structure of Human Fibronectin Defined by Monoclonal Antibody FDC-6," The Journal of Biological Chemistry, vol. 263, No. 7, pp 3314-3322, 1988.				
	4	ISEMURA et al., "Isolation and Characterization of Human Placenta Fibronectin," J.Biochem. 96, 163-169, 1984.				
		·	<u>-</u> .			

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.